MacroGenics recently reported strong financial results for the quarter, including a revenue increase and net income boost. The company's focus on B7-H3 assets like vobra duo and MGC026 shows promise for the future. CEO Dr. Scott Koenig highlighted ongoing clinical programs and future prospects.